Files in this item
Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapy
Item metadata
dc.contributor.author | Faratian, Dana | |
dc.contributor.author | Sims, Andrew H. | |
dc.contributor.author | Mullen, Peter | |
dc.contributor.author | Kay, Charlene | |
dc.contributor.author | Um, Inhwa | |
dc.contributor.author | Langdon, Simon P. | |
dc.contributor.author | Harrison, David J. | |
dc.date.accessioned | 2013-11-05T11:01:10Z | |
dc.date.available | 2013-11-05T11:01:10Z | |
dc.date.issued | 2011-08-31 | |
dc.identifier.citation | Faratian , D , Sims , A H , Mullen , P , Kay , C , Um , I , Langdon , S P & Harrison , D J 2011 , ' Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapy ' , PLoS One , vol. 6 , no. 8 , e23772 , pp. - . https://doi.org/10.1371/journal.pone.0023772 | en |
dc.identifier.issn | 1932-6203 | |
dc.identifier.other | PURE: 23159402 | |
dc.identifier.other | PURE UUID: c72ad816-acfa-4112-aaab-b0bdf0321fb2 | |
dc.identifier.other | WOS: 000294680800020 | |
dc.identifier.other | Scopus: 80052332155 | |
dc.identifier.other | ORCID: /0000-0001-9041-9988/work/64034239 | |
dc.identifier.uri | https://hdl.handle.net/10023/4157 | |
dc.description.abstract | Background: Resistance to trastuzumab is a clinical problem, partly due to overriding activation of MAPK/PI3K signalling. Sprouty-family proteins are negative regulators of MAPK/PI3K signalling, but their role in HER2-therapy resistance is unknown. Patients and Methods: Associations between Sprouty gene expression and clinicopathological features were investigated in a breast cancer microarray meta-analysis. Changes in expression of Spry2 and feedback inhibition on trastuzumab resistance were studied in SKBr3 and BT474 breast carcinoma cell lines using cell viability assays. Spry2 protein expression was measured by quantitative immunofluorescence in a cohort of 122 patients treated with trastuzumab. Results: Low gene expression of Spry2 was associated with increased pathological grade, high HER2 expression, and was a significant independent prognostic factor. Overexpression of Spry2 in SKBr3s resulted in enhanced inhibition of cell viability after trastuzumab treatment, and the PI3K-inhibitor LY294002 had a similar effect. Low Spry2 expression was associated with increased risk of death (HR = 2.28, 95% CI 1.22-4.26; p = 0.008) in trastuzumab-treated patients, including in multivariate analysis. Stratification of trastuzumab-treated patients using PTEN and Spry2 was superior to either marker in isolation. Conclusion: In breast cancers with deficient feedback inhibition, combinatorial therapy with negative regulators of growth factor signalling may be an effective therapeutic strategy. | |
dc.format.extent | 9 | |
dc.language.iso | eng | |
dc.relation.ispartof | PLoS One | en |
dc.rights | © 2011 Faratian et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | en |
dc.subject | Trastuzumab | en |
dc.subject | Breast cancer | en |
dc.subject | Protein expression | en |
dc.subject | Gene expression | en |
dc.subject | Biomarkers | en |
dc.subject | R Medicine | en |
dc.subject | SDG 3 - Good Health and Well-being | en |
dc.subject.lcc | R | en |
dc.title | Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapy | en |
dc.type | Journal article | en |
dc.description.version | Publisher PDF | en |
dc.contributor.institution | University of St Andrews. School of Medicine | en |
dc.identifier.doi | https://doi.org/10.1371/journal.pone.0023772 | |
dc.description.status | Peer reviewed | en |
This item appears in the following Collection(s)
Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.